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Bisphosphonates are considered first line therapy for the prevention and treatment of 
osteopenia and osteoporosis among post-menopausal women. They have proven efficacious in 
the reduction of fractures related to low bone mineral density. In the last few years, severe 
adverse effects have been linked to the long-term use of bisphosphonates, including 
osteonecrosis of the jaw and atypical femur fracture. In spite the fact that the aforementioned 
side effects are concerning for patients and providers, these complications are extremely rare 
compared to the prevalence of fractures among post-menopausal women. Currently, there are no 
definite guidelines for the duration of treatment with these medications. 
This paper evaluates the treatment plan for a 72-year-old female with osteoporosis. While 
she is considered a high-risk patient due to a recent fracture and a T-score of -2.6, she is not on 
anti-osteoporosis medication. Through this report, selection of a bisphosphonate drug and 
duration of treatment for this particular patient will be addressed. 
In order to better understand how to manage osteoporosis treatment with 
bisphosphonates, a review of the literature was conducted. MEDLINE, CINAHL, PubMed and 
Cochrane databases were searched. Articles from peer-reviewed journals, systematic reviews, 
retrospective studies and current guidelines from bone health organizations were reviewed. This 
research allows for a much clearer understanding of the association between bisphosphonates 
and severe adverse effects, and their role in the prevention and treatment of osteopenia and 








After the age of 40, an imbalance between bone breakdown and bone regeneration occurs 
due to changes in cell activity involved in bone tissue maintenance. In women, this imbalance 
accelerates after menopause due to the loss of estrogen and bones become weak, increasing their 
risk of fractures (American Academy of Orthopedic Surgeons, 2019). Estrogen-receptors 
activation in bone tissue sustain a synchronized process between osteoblasts, the cells that 
promote bone regeneration, and osteoclasts, the cells that break down bone, sustaining healthy 
bone tissue (Khalid & Krum, 2016). However, during menopause estrogen receptors are no 
longer activated resulting in an imbalance between building and destruction of bone. Osteoblasts 
slow down while osteoclasts continue to work at the same rate as they did in earlier years (Mayo 
Clinic, 2019) leading to the formation of weaker bones. Is in this scenario that osteopenia and 
osteoporosis develop. The standard method for measuring bone mineral density (BMD) is the 
axial dual-energy X-ray absorptiometry (DXA) (American Association of Clinical 
Endocrinologists & American College of Endocrinology, 2016). The result of this test is reported 
as a T-score and is interpreted according to the World Health Organization criteria for the 
diagnosis of osteoporosis. A T-score of -1.0 or above indicates a normal BMD, a T-score 
between -1.0 and -2.5 is considered low BMD or osteopenia, and a T-score of -2.5 or below 
confirms diagnosis of osteoporosis (National Osteoporosis Foundation, 2019).  
The case study in this paper concerns a 72-year-old female who comes to the clinic for a 
6-week follow up after being in the hospital for 3 days. She sustained a fall and broke her right 
hip. During her hospital stay she had an open reduction internal fixation (ORIF) surgery. This 
patient is a smoker and has been on oral steroid medications intermittently due to COPD. She is 
also on inhaled corticosteroids daily. Currently, she is neither on any anti-osteoporosis 
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medication nor on calcium-vitamin D supplements. She has never received treatment for 
osteoporosis in the past. This patient has a diagnosis of osteoporosis according to her most recent 
DXA scan, done 2 years ago, with a T-score of -2.6. According to most bone health 
organizations’ recommendations, this patient should initiate pharmacologic treatment. This 
review focuses on the use of bisphosphonates in the management of osteoporosis. 
Bisphosphonates (BP) are considered first line therapy for the prevention and treatment 
of bone density loss among post-menopausal women. They work by inhibiting osteoclasts 
activity allowing more time for bone matrix regeneration by osteoblasts (American Bone Health, 
2019). The efficacy of BP in reducing fracture risk has been strongly proven in 3 main studies: 
The FIT-FLEX study, the HORIZON and its extension trial, and the VERT-MN study. These 
studies evaluated alendronate, zoledronate and ibandronate respectively. The authors concluded 
that full benefits of BP therapy can be achieved within a treatment period of 3 to 5 years, 
depending on the drug used. After this period, guidelines are not definite, leaving clinicians in a 
blurry path for treatment planning.  
New discussions on BP therapy length have taken place due to concerns about severe 
adverse effects and based on the particular pharmacologic activity of these drugs. Research on 
the mechanism of action of BP has shown that after stopping the intake of these medications, 
their bone-protective function remains in the body. These drugs accumulate in bone tissue 
creating a reservoir of BP that maintains the inhibition of osteoclasts resorptive activity. In 
addition, investigations have shown that long-term use of BP has been associated with severe 
complications such as osteonecrosis of the jaw (ONJ), atypical femur fracture (AFF) and 
esophageal cancer (Schneider, 2015). Although the risk of these adverse effects is low, in 2011 
the FDA suggested a review of BP therapy with clarification on the duration of bisphosphonate 
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use. The panel of experts was unable to get to a conclusion (Diab & Watts, 2013), however, and 
instead they declared a limitation of bisphosphonate use - “The optimal duration of use has not 
been determined. All patients on bisphosphonate therapy should have the need for continued 
therapy must be re-evaluated on a periodic basis” - FDA (Adler et al., 2016).  
In order to properly delineate a plan for the management of osteoporosis for the patient in 
the case study, it was necessary to undertake a review of the literature to understand more clearly 
the prevalence of the severe side effects mentioned earlier after long-term intake of BP, and to 
evaluate the efficacy of bisphosphonates in the reduction of fractures. The purpose of this paper 
is to search for studies conducted to define the ideal duration of bisphosphonate therapy, and to 
review current practices and recommendations that can aid providers when deciding whether to 
star/restart, pause or stop bisphosphonate therapy. 
Case Report 
Allergies: none 
Immunizations: Influenza 11/2018, Tdap 5/2015, Zoster live 5/2016, PCV13 1/2018 




Mary Jones is a 72-year-old female Caucasian patient, she is here for a follow up after being 
discharged from the hospital 6 weeks ago. She had a right hip surgery due to a “silly” fall she 
sustained when walking from her living room to the kitchen. She lost her balance trying to not to 
step on her little dog, she fell on her knee first and then she fell over her right side. She was 
surprised to find out that she broke her hip and not her knee.  
 
Today she is doing good. She rates her pain at 3/10. Pain increases to 5/10 when doing her 
exercises but after taking Tylenol she is ok. She feels slightly fatigued but doing most of her 
shores by herself. She is using a walker to ambulate. Her children are helping her with groceries 
but other than that she is able to live independently in her house as she was before the fracture.  
 
She would like also to establish care today. She tells me she has history of COPD, depression, 
anemia, hypertension, hypercholesterolemia and osteoporosis. She is a smoker. She smokes a 
pack per day, she has been doing it for more than 30 years.  
 
 

























Mother   
No siblings 
 
She is a widow, living independently at home. 
She has 2 children who live in town and they 
have been helping her with shores because of 
the surgery. Occupational history: retired 
teacher. 
Smoke/alcohol/drugs: Smoker, 1 pack per day 
for more than 30 years/never used 




Fluticasone propionate and salmeterol 250/50 1 puff BID  
Prednisone taper for COPD flare (completed yesterday) 
Losartan 50 mg PO daily 
Metoprolol 50 mg PO BID 
Paroxetine 20 mg PO daily 
Quetiapine 200 mg PO BID 
Lipitor 20 mg PO QD 
Multivitamin PO daily 
Iron sulfate 325 mg PO BID 
 
Review of Systems:  
Constitutional: Negative for diaphoresis. Negative for fever/chills. Has fatigue, denies insomnia. 
Appetite is good.  
HENT: Negative for ear pain/tinnitus, postnasal drip, rhinorrhea, sinus pain, sinus pressure or 
sore throat. Eyes: negative for pain/discharge/visual changes. 
Respiratory: Negative for cough. Negative for shortness of breath/chest tightness. Negative for 
wheezing. 
Cardiovascular: Negative for chest pain. Negative for palpitations. Negative for syncope. 
Endocrine/hematology: negative for heat/cold intolerance. Negative bleeding. Some bruising on 
her right thigh from surgery. Small bruise on her right knee. 
Gastrointestinal: Negative for abdominal pain. Negative for N/V. Negative for blood in stool. 
Negative for diarrhea. Has constipation occasionally.  
Musculoskeletal: her right hip feels a little stiff still. Pain is ok. 
GU: Negative for dysuria/frequency/blood in urine. Negative for retention. 
Skin: Negative for rashes/lumps/bumps/surgical wound on right hip. 
Neurological: Negative for dizziness, numbness/tingling. Headaches. 
Psychiatric/Behavioral: depression is ok. 
 
Physical Exam:  
BP 138/70, Pulse 72, Temp 98.6 F, R 18, SpO2 92%, Wt 125 lb., H 5’8”, BMI 19.0 
 
Constitutional: She is oriented to person, place, and time. She appears well-developed and well-
nourished.  
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HENT: Head: Normocephalic, atraumatic. 
Right Ear: TM is visible and intact. Appears normal, pearly gray color. Left Ear: TM is visible 
and intact. Appears normal, pearly gray color.  
Nose: mucosa looks moist and pink.  
Eyes: Conjunctivae and EOM are normal. Pupils are equal, round, and reactive to light.  
Neck: Neck supple. No thyromegaly noted. No lymphadenopathy noted. 
Cardiovascular: Normal rate and regular rhythm. No murmur, rub or gallops noted. 
Pulmonary/Chest: Effort normal and breath sounds diminished. Lungs are clear to auscultation. 
No wheezing. 
Abdominal: Soft. Bowel sounds are normal.  
Neurological: She is alert and oriented to person, place, and time. She has normal reflexes. 
Skin: Skin is warm and dry. Surgical wound to her right hip looks great, healing, edges 
approximated. Sutures are out. The wound is open to air. There is slight bruising and edema to 
the area. No signs of infection. 
Right leg: sensation is intact and pulses (popliteal, posterior tibial and dorsalis pedis) are 
palpable and equal. Movement of the hip remains slightly restricted because of the surgery and 
pain. 
Psychiatric: She has a normal mood and affect. Her behavior is normal. Judgment and thought 
content normal.  
 
Assessment and Plan:  
M80.051 Age-related osteoporosis with current pathological fracture, right femur 






Will focus on post-hospital discharge and osteoporosis management today and I will highlight 
some of the things I would address with Mary in following visits. I do not want to overwhelm 
her with too much information today. Labs ordered: BMP, CBC. Imaging ordered DXA scan. 
 
Post-hospital discharge: will order CBC since she is feeling tired, she is status post-surgery and 
has history of anemia.  
Osteoporosis: will order kidney function test and calcium levels (BMP). If all ok and given that 
she has osteoporosis, had recent fracture, she is a smoker, she is on daily inhaled corticosteroids 
and intermittent oral steroids, will start her on Alendronate 70 mg PO weekly. Take on empty 
stomach with a full glass of water. Do not lay down for 30 min to an hour after taking the 
medication. Do not eat or take other medications with alendronate, wait at least 30 min. Side 
effects: bone, joint or muscle pain, nausea, difficulty swallowing, heartburn, irritation of the 
esophagus and gastric ulcer. Severe adverse effects osteonecrosis of the jaw, atypical femur 
fracture and esophageal cancer. I reassured her that these are rare and normally associated with 
high doses and long-term use of bisphosphonates, normally over 10 years with alendronate. Will 
start her on calcium 1,200 mg daily + vitamin D 1,000 IU daily as well. 
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Fall prevention education included: no lose rugs at home, grab bars in the bathroom, well-lit 
rooms. Weight bearing exercises, as well as balance exercises. Make sure you know where your 
little dog is before walking. Use your walker until you are discharged from its use. 
Bone health: smoking cessation, exercise, calcium and vitamin D supplement. Try to stay away 
from steroids. 
 
She agreed to pneumonia vaccination (PPSV23) today. Does not want the new Shingrix vaccine. 
 
I will see her in one month follow up for establishing care labs or she can return to the clinic if 
new concerns or problems manifest before that time.  
1 year follow up for osteoporosis will repeat a DXA scan to monitor BMD and will assess 
fracture risk with FRAX. Will have her taking alendronate for 3-5 years depending on response 
to therapy. She agreed with plan. 
 
Following visits: 
Smoker: For Mary I suggested lung cancer screening, she refused. I offered tobacco cessation 
services, she said she will think about it. Will emphasize the relationship between smoking and 
COPD exacerbations and will educate her about detrimental effects of smoking on bone health. 
We can talk more about it on the next visit. 
COPD: she says that this is well controlled right now with her inhaler. Will talk more about 
COPD maintenance during next visit. 
Hypertension: well controlled with metoprolol and losartan. Will check urine microalbuminuria 
next visit. 
Hypercholesterolemia: will order lipid panel and hepatic panel for next visit. 
Anemia: She is on Iron sulfate. She says she is feeling tired. Will check CBC. 
Depressions: well controlled with paroxetine and quetiapine. 
 
Other screening suggestions: colonoscopy, she does not want to have another done, had a 
colonoscopy 5 years ago, no polyps found. Will talk about FOBT on next visit. Mammogram: 
she had a mammogram 5 years ago. We may suggest one last mammogram before she turns 74. 
Previous were normal, no history of breast cancer in her family, she is a smoker. 
 
American Association of Clinical Endocrinologists/American College of Endocrinology. (2016). Clinical practice 
guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocrine Practice, 22(4). 
Retrieved from: https://www.aace.com/files/postmenopausal-guidelines.pdf 
Chee, C., Sellahewa, L., & Pappachan, J. M. (2014). Inhaled corticosteroids and bone health. The Open Respiratory 
Medicine Journal, 8, 85-92. doi:10.2174/1874306401408010085 
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., Lindsay, R., National 
Osteoporosis Foundation (2014). Clinician's guide to prevention and treatment of osteoporosis. 
Osteoporosis International: a journal established as result of cooperation between the European 
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 25(10), 2359-81. 




In evaluating an osteoporosis treatment plan for the patient in the case study, the 
literature was reviewed using CINAHL, PubMed, MEDLINE and Cochrane Library via the 
Harley French Library at the University of North Dakota. The search terms used included 
“bisphosphonate”, “duration”, “osteoporosis”, “cessation”, “drug holiday”. Results were limited 
to English language, human studies, bisphosphonates in the treatment of osteoporosis and 
publish date after 2013. This resulted in 110 articles. Twelve articles were retained (5 systematic 
reviews, 4 randomized controlled trials and 3 peer-reviewed journal articles) based on abstract 
review and on their ability to aid in care planning for patients with post-menopausal 
osteoporosis. New prospective studies evaluating the benefits and risks of bisphosphonate 
therapy are limited. A popular literature search was also conducted to inquire about the 
mechanisms of action of bisphosphonates, the prevalence of osteoporosis in the aforementioned 
population and the costs associated with fractures related to low BMD. 
Ultimately, the review of the literature should help the author of this paper to select an 
adequate BP drug for the patient in the case study, guide her on how to monitor patient status and 
success of therapy, and help her to define duration of the therapy (addressed on the plan 
described in the case study). 
Prevalence and Cost of Osteoporosis 
Osteoporosis and the related fractures are costly. A study done by Wright et al. (2014), 
estimated that among the older population (>50 years old) in the USA, osteoporosis and 
osteopenia are prevalent in approximately 53.6 million people, with women and non-Hispanic 
whites being the most affected. In terms of costs, low BMD-related fractures have been 
evaluated at $19 billion per year and calculated to increase up to $25.3 billion by 2025 (National 
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Osteoporosis Foundation, 2015). Although not the focus of this paper, it is worth noting that 
screening should be a clinician’s priority when taking care of post-menopausal women. 
Bisphosphonates 
Given that osteoporosis represents a major risk for broken bones with the associated 
increase in morbidity, mortality and public health burden, medications have been developed to 
manage this condition. Bisphosphonates are considered safe and effective for the treatment of 
osteoporosis in post-menopausal women. Studies have shown that these medications are able to 
reduce vertebral fractures (40-70%), hip fractures (20-50%) and nonvertebral fracture (15-39%) 
(Adler et al., 2016). The numbers speak clearly about their efficacy. Bisphosphonates approved 
by the FDA for the prevention and treatment of osteoporosis in post-menopausal women are 
alendronate, zoledronate, risedronate and ibandronate (American Bone Health, 2019). They 
belong to the drug class called pyrophosphate analogues. They work by inhibiting bone 
resorption by the osteoclasts. They show a strong chemical likeness for bone tissue giving them a 
long half-life within the skeleton. Because of this particular characteristic, BP accumulate on 
bone surface allowing these drugs to provide residual treatment and to continue to inhibit 
osteoclast activity, even after discontinuation of therapy has occurred (Meier et al., 2017). Their 
affinity for bone varies from drug to drug being zoledronate the BP with the longest half-life, 
followed by alendronate, ibandronate and risedronate in order of decreasing affinity (Diab & 
Watts, 2013).  
Risks Associated with the use of Bisphosphonates 
 Unfortunately, as any other medication, bisphosphates are not free of side effects, 
and their remanent activity can be good or bad. Recently, concerns about severe side effects 
associated with the intake of bisphosphonates have emerged. The most severe adverse effects 
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associated with the intake of BP are ONJ, AFF and esophageal cancer (Villas, Giannakos & 
Lane, 2015). According to Villas et al. (2015), the association of ONJ and bisphosphonates 
therapy exists. This rare condition has been observed in patients taking bisphosphonates for 4 
years or more. Nevertheless, the causation cannot be proven given that ONJ has been found in 
patients who are not taking these medications. In regard to AFF, the conclusions are similar. The 
association of BP with AFF has been observed in treatment duration of near 10 years, yet, 
causality has not been established. For esophageal cancer, the malignancy was observed in 
patients who had more than 10 bisphosphonate prescriptions. In another important study Adler et 
al., (2016) found that the incidence of ONJ was 1/10,000 to 1/100,00 and in those who developed 
the condition while taking bisphosphonates, this was mild and went away with conservative 
treatment or without it. This study noted some of the risks associated with the development of 
ONJ as well. To mention poor oral hygiene, smoking, diabetes mellitus, related use of 
medications such as glucocorticoids and/or chemotherapy drugs, and invasive dental procedures 
(i.e. implants, extractions). For the incidence of AFF, this same study found that 1.8 patients out 
100,000 per year developed AFF after a 2-year exposure to bisphosphonates versus 113 patients 
out of 100,000 with 8 to 9.9 years of exposure. These results support the fact that AFF incidence 
increases with prolonged bisphosphonate therapy. Meier et al. (2017), found similar results and 
calculated the incidence of ONJ to be 0.01% to 0.025% with increasing numbers as treatment 
duration lengthens. This investigation also calculated a low risk of AFF ranging from 3.2 to 50 
cases per 100 000 person‐years. Neither Adler et al. nor Meier et al. evaluated the incidence of 
esophageal cancer among patients taking BP. It is important to note that FDA has not enforced 
package labeling with warnings for esophageal carcinoma while on BP therapy (Adler et al., 
2016).  
Running head: DURATION OF BISPHOSPHONATE THERAPY FOR THE TREATMENT OF OSTEOPOROSIS. 
 
13 
These statistics should be compared to the higher prevalence of fractures in patients with 
low BMD. A Recent survey done by the National Osteoporosis Foundation (2017) indicates that 
1 in 2 women over the age of 50 will sustain a fracture related to low BMD. In spite the fact that 
ONJ, AFF and esophageal cancer are severe and concerning side effects for patients and 
providers, their occurrence is rare while the prevalence of fractures among women with 
osteoporosis is high. Treatment with bisphosphonates should not be dismissed. The patient in the 
case study would benefit from BP therapy. 
Other adverse effects linked to the intake of bisphosphonates are atrial fibrillation, kidney 
damage and acute gastrointestinal intolerance. Currently, the FDA appraises the association 
between atrial fibrillation as weak. To protect kidney function, BP should not be prescribed for 
those with creatinine clearance below 30-35 ml/min. For those patients with gastrointestinal 
intolerance intravenous bisphosphonate should be considered (Adler et al., 2016).  
Duration of Therapy 
 New studies evaluating BP and their associated risks are limited and 
recommendations on duration of treatment remain evasive. There are 3 important studies done in 
the past. These studies are still considered relevant today and bone health organizations such as 
the National Osteoporosis Foundation (NOF), the American Association of Clinical 
Endocrinologists (AACE) and the American Society for Bone and Mineral Research (ASBMR) 
have written recommendations based on these studies to aid the clinician in the management of 
patients with low BMD. These classic studies are the FIT-FLEX study, the HORIZON and its 
extension trial, and the VERT-MN study (Lee et al., 2015). In the FIT-FLEX study, alendronate 
was evaluated. The authors compared 5 years of therapy versus 10 while investigating the effects 
of alendronate on BMD, bone turn over markers (BTM) and fracture risk. The study found no 
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difference between the two groups. It is worth to note that post hoc analyses observed that for 
those with a femoral neck T-score of < -2.5, longer treatment with alendronate reduced risk of 
non-vertebral fractures in 50% of the cases (Reid, 2015). In the HORIZON study and its 
extension trial, zoledronate was evaluated during a 3-year treatment period versus 6 years. The 
study yielded similar results to the ones in the FIT-FLEX study. There was no difference in 
fracture risk between the group who received treatment with zoledronate for 3 years versus the 
group who receive treatment for 6 years. Yet, they noted that those who received treatment for a 
longer period had more stable BMD and BTMs compared to the subjects who received 
zoledronate for only 3 years. The authors concluded that for those individuals with high risk of 
fractures, longer treatment with zoledronate may be appropriate (Villa, Gianakos, & Lane, 2016). 
Nevertheless, Adler et al. (2016) in their extensive research suggested that the association 
between stable BMD or BTM and lower fracture risk is weak. In the VERT-MN study, 
risedronate was evaluated to seven years. The study showed a significant reduction in the risk of 
vertebral fractures (65%) (Schneider, 2015). In a follow up study, Black et al., (2014) conducted 
a 3-year, multicenter, randomized, double blind, second extension study of the HORIZON trial 
to evaluate the benefits of treatment extension with zoledronate from 6 years to 9 years. The 
study did not show any evidence of better BMD, BTMs or reduction of fracture risk. 
Interestingly, the investigators observed a small increase in cardiac arrhythmias with treatment 
duration of 9 years. They concluded that treatment with zoledronate should stop at the sixth year 
of therapy, and stated that residual activity of zoledronate remains for 3 additional years after 
cessation of BP intake. 
International studies have been also conducted to evaluate BP therapy and to review 
current recommendations. A retrospective cohort study done in Taiwan was conducted in a 
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population of 1342 women with a mean age of 71 over a period of 10 years, to evaluate the 
effects of continuing alendronate therapy to reduce fracture risk beyond the standard 5 year-
therapy. The study found no additional benefits in continuing therapy beyond this time. The 
investigators did not have data in order to assess any changes in BMD of the population studied, 
however. Interestingly the study did not find changes in fracture risk among patients who were 
not completely compliant with BP intake, given the long half-life of these medications, and 
concluded that a gap of up to 18 months should not affect fracture risk. They did not observe any 
AFF during the course of the investigation (Wang, Lu, Dusetzina & Wu, 2016). The Swiss 
Association against Osteoporosis (2017) has also established guidelines based on current 
recommendations, to manage osteoporosis. They suggest that oral BP therapy should be 
prescribed for 5 years while intravenous therapy for only 3. Patients monitoring is warranted 
with DXA scan every 2-3 years. Patients should be classified as low or high risk. Those at low 
risk for fracture can stop bisphosphonate and should be encouraged to maintain bone health with 
calcium and vitamin D supplements. High risk patients should continue with therapy but 
switched from bisphosphonates to another type of medication such as denosumab (human 
monoclonal antibody) (Meier et al., 2017). Finally, in a Japanese study, ibandronate was 
evaluated. The investigators suggested that therapy for five years was considered adequate and 
patient should be re-evaluated after 1-2 years after withdrawal from therapy (Hagino et al., 
2014). 
In summary, duration of treatment should be up to 5 years with oral bisphosphonates and 
up to 3 with intravenous bisphosphonates. Patients who after therapy are at low risk of fracture 
can stop treatment, while those who remain at moderate to high risk may benefit from continuous 
oral BP therapy for up to 10 years or up to 6 years with intravenous BP therapy. For those 
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patients who continue with treatment monitoring for severe side effects is essential. Clinicians 
should re-assess patient status in those who present with thigh or groin pain especially in the 
absence of trauma. This symptom has been associated with AFF. Therapy with bisphosphonate 
should be discontinued, imaging should be obtained and consultation with orthopedics placed in 
this case (Reid, 2015). This is an important patient education fact. 
Drug Holiday 
A Drug holiday is a concept that emerged as a method to take advantage of the benefits 
of a drug while minimizing the risk of severe adverse effects associated with its long-term use. 
Lee et al., (2015) conducted a South Korean Study in which a drug holiday is proposed for the 
management of low risk patients with osteoporosis. The authors in this study created a simple 
algorithm for patients on alendronate, risedronate and zoledronate. A drug holiday should be 
offered after 5 years for those on alendronate and risedronate, and after 3 years for those on 
zoledronate. Annual assessment of the patient’s risk fracture should be conducted with 
measurements of BMD. Re-initiation of therapy should be established if patient declines in bone 
health (i.e. T-score ≤-2.5, new osteoporotic fracture). The FDA agrees to drug holidays but 
warns that high risk patients may benefit from continuation of therapy with BP or non-BP drug 
(Diab & Watts, 2013). 
 On the other hand, if the patient is considered at high fracture risk, normally defined as 
those who have a T-score of < -2.5, have had a fracture and have secondary osteoporosis due to 
medications and comorbidities, continuation of therapy or switching to a different treatment 
should be offered.  
A French retrospective cohort study done to evaluate the effects of drug holiday with 
alendronate, risedronate, zoledronate and ibandronate in a population of women with 
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osteoporosis, showed that after cessation of therapy and within a period of 6 to 36 months the 
risk of fractures increased to 40% (Legroux, Cortet, Paccou, Mignot & Taisne, 2017). The study 
was small, however.  
As a general rule the length of a drug holiday should be instituted according to the bone 
tissue affinity of the drug, and re-evaluation of the patient status should be done in 1-2 years after 
cessation of alendronate, ibandronate and risedronate and in 2-3 years after cessation zoledronate 
(Diab & Watts, 2013).  
Patient Monitoring 
 Guidelines on how to monitor treatment with BP are not clear. DXA scan is the most 
widely used tool for monitoring BMD. Some literature suggest that monitoring can be done with 
measurements of BTMs such as bone alkaline phosphatase, osteocalcin, C-terminal propeptides 
of type I collagen (CTX) and NTX. Urine bone resorption markers include breakdown products 
of type I collagen such as pyridonium cross-links (PYR and D-PYR) (Khalid & Krum 2016). 
Limited studies have been conducted to assess the accuracy of bone health monitoring. One of 
those studies is an investigation conducted by Bauer et al. (2014), this was prospective study to 
follow the placebo patients from the FLEX investigation. They wanted to evaluate methods to 
better assess fracture risk in patients with low BMD after stopping treatment with alendronate. 
The study concluded that a better prediction of fracture risk is done by noting the age and BMD 
at the hip at cessation of therapy rather than with yearly DXA scans or BTMs.  
Important organizations have tried to write guidelines. The ASBMR (2016) recommends 
that after 5 years of oral BP or 3 years of intravenous BP, re-assessment of patient’s risk should 
be considered. Nevertheless, the ASBMR fails to recommend a method given that studies have 
not shown that measurement of BMD, BMTs or fracture-risk assessment such as with the World 
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Health organization FRAX tool, are able to accurately predict fracture risk among patients with 
osteoporosis (Adler et al., 2016). On the other hand, the AACE and the American College of 
Endocrinology (ACE) (2016), recommend that monitoring of the patient’s bone health should be 
done with DXA scan every 1-2 years until stable, meaning there is an increase in BMD and 
absence of new fractures. Clinicians may use BTMs to monitor patient’s compliance with 
therapy and effectiveness of therapy as well. 
Finally, the NOF (2014), proposes that measurement of height and measurement of BMD 
with DXA scan are essential for therapy evaluation. This should be done after one year of 
initiation of therapy and one to two years after that. BTMs can be used as a secondary tool to 
assess the effects of treatment.  
In summary, assessment of patient status and efficacy of therapy can be done using 
different tools, being the most relevant the incidence of new fractures. 
Learning Points. 
-Bisphosphonates are effective in the treatment of osteoporosis and in the reduction of risk of 
fractures in post-menopausal women. Each bisphosphonate has a different half-life therefore 
duration of treatment, drug holiday and interval of patient monitoring should be established 
according to the particular characteristics of the drug.  
-Adverse risk effects such as ONJ and AFF are rare and have been observed with high doses of 
and/or long-term treatment with bisphosphonates. 
-All patients should be offered a drug holiday. High risk fracture patients may be better off with 
continuation of BP therapy or switching to a non-bisphosphonate anti-osteoporosis drug. 
Treatment should be individualized and should incorporate patient preferences and clinician 
judgement. 
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